Tesamorelin Before and After: What the Trials Measured (Belly Fat, Not Muscle)

In the two trials behind its FDA approval, tesamorelin reduced visceral (deep abdominal) fat by 18% and 14% over 26 weeks, against roughly no change on placebo. Body weight did not change, and when people stopped, the fat came back within six months. That is the honest before-and-after: a measurable change in belly fat on a CT scan, in adults with HIV-associated lipodystrophy — not a leaner, more muscular body in anyone who injects it.

What changes did tesamorelin produce in its trials?

Tesamorelin (brand name Egrifta) is FDA-approved for one use: "the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy"¹. Two randomized, placebo-controlled trials of about 400 people each measured visceral fat by CT scan at 26 weeks¹²³:

• •Visceral fat: down 27 cm² (18%) in Study 1 and 21 cm² (14%) in Study 2. Placebo: up 4 cm² and flat¹.
• •Waist: down about 2 to 3 cm, against 1 cm on placebo¹.
• •Trunk fat: down 0.8 to 1.0 kg¹.
• •Body weight: essentially unchanged — minus 0.4 kg in one trial, plus 0.5 kg in the other¹.

So in a photo, the change is a smaller waist, not a lower number on the scale.

How long until visceral fat drops, and does it come back?

The trials measured at 26 weeks, so six months is the timeline the evidence supports. After that, people who finished the first phase on tesamorelin were re-randomized to keep taking it or switch to placebo for another 26 weeks¹. People switched to placebo regained visceral fat — up 22% in Study 1 and 16% in Study 2 — while people who stayed on tesamorelin held their result¹. The label tells prescribers to weigh continuing treatment in patients who have not had a reduction in visceral fat¹. In short: the effect lasts only as long as the injections do.

Does tesamorelin build muscle or help non-HIV weight loss?

Weight loss: no. The label says it "is not indicated for weight loss management as it has a weight neutral effect"¹.

Muscle: not shown. Lean body mass rose about 1.2 to 1.3 kg on scans in the trials¹, but lean mass includes water and organs, and the trials did not measure strength or performance. Tesamorelin raises IGF-1, and the label lists fluid retention among its warnings¹.

People without HIV: the approval rests on HIV lipodystrophy trials only. Any other use — including compounded tesamorelin sold for body composition — is off-label, without the same evidence behind it.

What side effects did the label report?

Over the first 26 weeks, more people on tesamorelin than on placebo reported¹:

• •Injection site reactions (17% vs 6%)
• •Joint pain (13% vs 11%)
• •Muscle pain (6% vs 2%) and swelling in the legs or arms (6% vs 2%)
• •Tingling or numbness (5% vs 2%)

It also raised the risk of developing diabetes: 5% vs 1%¹. Our tesamorelin side effects article covers the full list.

How does it compare with sermorelin?

Both stimulate the body's own growth hormone release, and both are banned in sport. The difference is evidence: tesamorelin has a current FDA label and two phase 3 trials with a measured outcome. Sermorelin's FDA-approved product, Geref, was discontinued, so no current label exists, and it has no trial measuring visceral fat. Our sermorelin vs. tesamorelin comparison goes through both. For sermorelin's own before-and-after evidence, see what the sermorelin studies show.

What do sellers charge?

Few telehealth sellers publish a tesamorelin price. Of the seven reviewed sellers whose sites list it, only one shows a figure, and that figure is a six-month rate:

• •Live Vital review: listed in its catalog; most products are sold as multi-week protocols.
• •Magnolia Regenerative Medicine review: on its menu; its advertised figures are prepay rates.
• •Oak review: priced only after an assessment.
• •Rehydra+ Wellness review: six-month memberships only.
• •RxPepsDirect review: priced per vial, not per month.
• •TeleZen MD review: an intake page that its main site never mentions.
• •Trellis Vitality review: "$299", which its own page says is a six-month rate.

Listed alphabetically. The prices we could read on sellers' own tesamorelin pages, including Nuform Health's $220 a month on a two-month plan, are side by side in our tesamorelin provider comparison.

The approved dose is 1.4 mg once daily for Egrifta SV, or 1.28 mg once daily for Egrifta WR — the two are not interchangeable¹. Our tesamorelin dosing article covers the label, and the tesamorelin calculator does the vial math. The sermorelin sellers we track are the closest priced comparison.